The effects of statins on prevention of stroke and dementia

Journal of Cardiopulmonary Rehabilitation and Prevention

Volumn 32, Issue 5, 2012, Pages 240-249

  Menezes, Arthur R ^a   Lavie, Carl J ^a,b   Milani, Richard V ^a   O'Keefe, James ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DEMENTIA; DRUG EFFECT; DRUG MEGADOSE; DRUG USE; FOLLOW UP; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; META ANALYSIS (TOPIC); NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

DEMENTIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 84865963716     PISSN: 19327501     EISSN: 1932751X     Source Type: Journal    
DOI: 10.1097/HCR.0b013e31825d2a03     Document Type: Review

References (94)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
2. Centers for Disease Control and Prevention. Prevalence of stroke-United States, 2005. MMWR. 2007;56:469-474.
3. Centers for Disease Control and Prevention. Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke. MMWR. 2005;54:113-117.
4. Stansbury JP, Jia H, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes. Stroke. 2005;36:374-387.
5. Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety? Mayo Clin Proc. 2007; 82:539-542.
6. Lavie CJ, Milani RV, O'Keefe JH. Does the choice of statin really matter? Postgrad Med. 2010;122:243-247.
7. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17:92-100.
8. Hoeg JM. Evaluating coronary heart disease risk. Tiles in the mosaic. JAMA. 1997;277:1387-1390.
9. Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Risk factors. Stroke. 1997;28:1507-1517.
10. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet. 1995;346(8991/8992):1647-1653.
11. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, et al. Blood ch olesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet. 2007;370:1829-1839.
12. Harmsen P, Lappas G, Rosengren A, Wilhelmsen L. Long term risk factors for stroke. Twenty eight years of follow-up of 7457 middleaged men in Goteborg, Sweden. Stroke. 2006;37:1663-1667.
13. Sacco RL. The 2006 William Feinberg lecture: shifting the paradigm from stroke to global vascular risk estimation. Stroke. 2007;38:1980-1987.
14. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,997 men screened for the Multiple Risk Factor Interventional Trial. N Engl J Med. 1989;320:904-910.
15. Navi BB, Segal AZ. The role of cholesterol and statins in stroke. Curr Cardiol Rep. 2009;11:4-11.
16. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361:1529-1538.
17. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep. 2005;53:1-48.
18. Sabbagh MN, Sparks DL. Statins to treat Alzheimer's disease: an incomplete story. Expert Rev Neurother. 2012;12:27-30.
19. LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol. 2007;100:747-752.
20. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463.
21. Kurth T, Everett BM, Buring JE, et al. Lipid levels and the risk of ischemic stroke in women. Neurology. 2007;68:556-562.
22. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
23. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
24. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med. 1998;339:1349-1357.
25. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
26. Waters D, Schwartz GG, Olsson AG. The myocardial ischemia reduction with acute cholesterol lowering (MIRACL) trial: a new frontier for statins? Curr Control Trials Cardiovasc Med. 2001;2:111-114.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
28. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366: 895-906.
29. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
30. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
31. Owen OG. The Collaborative Atorvastatin Diabetes Study: preliminary results. Int J Clin Pract. 2005;59:121-123.
32. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
33. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
34. Waters DD, LaRosa JC, Barter P, et al. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2006;48:1793-1799.
35. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
36. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study. N Engl J Med. 1995;333:1301-1307.
37. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 1998;97:1440-1445.
38. Goldstein LB. Statins for stroke prevention. Curr Atheroscler Rep. 2007;9:305-311.
39. Shepherd J, Bla uw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
40. Milani RV. Lipid and statin effects on stroke and dementia. Am J Geriatr Cardiol. 2004;13(3) (suppl 1):25-28.
41. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
42. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
43. Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572-582.
44. Lees KR, Walters MR. Acute stroke and diabetes. Cerebrovasc Dis. 2005;20(suppl 1):9-14.
45. Suarez JI. Acute myocardial infarction, ischemic stroke, sympathetic stress, and inflammation: birds of a feather. Stroke. 2006;37:2449-3450.
46. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
47. Huisa BN, Stemer AB, Zivin JA. Atorvastatin in stroke: a review of SPARCL and subgroup analysis. Vasc Health Risk Manag. 2010;6:229-236.
48. Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124:2233-2242.
49. Athyros VG, Tziomalos K, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol. 2010;25:406-410.
50. Goldstein LB, A marenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24 Pt 2):2364-2370.
51. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
52. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295-2322.
53. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279:509-514.
54. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature.1997;389:990-994.
55. Katsumata N, Shimokawa H, Seto M, et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1. Circulation. 1997;96:4357-4363.
56. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005;96:24-33.
57. Marschang P, Friedrich GJ, Ditlbacher H, et al. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Int J Cardiol. 2006;106:183-190.
58. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004;10:183-190.
59. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:58-63.
60. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci. 2002;23:482-486.
61. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
62. DiNapoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke. An independent prognostic factor. Stroke. 2001;32:917-992.
63. DiNapoli M, DiGianfilippo G, Sollecito A, Bocola V. C-reactive protein and outcome after first-ever ischemic stroke. Stroke. 2000;31:231-239.
64. Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly. The Cardiovascular Health Study. Circulation. 2003;108:166-170.
65. Laufs U, Fata VL, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
66. Kureishi Y, Luo Z, Shijima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
67. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated downregulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725-31729.
68. Gillum RF, Yorrick R, Obisesan TO. Population surveillance of dementia mortality. Int J Environ Res Public Health. 2011;8:1 244-1257.
69. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag. 2010;6:775-785.
70. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257:85-90.
71. Sabbagh MN, Thind K, Sparks DL. On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks. Alzheimer Dis Assoc Disord. 2009;23:303-305.
72. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344-350.
73. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwelling elderly people. Arch Neurol. 2002;59:223-227.
74. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627-1631.
75. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc. 1997;45:8-14.
76. Muangpaisan W, Brayne C. Alzheimer's Society Vascular Dementia Systematic Review Group. Systematic review of statins for the prevention of vascular dementia or dementia. Geriatr Gerontol Int. 2010;10:199-208.
77. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217-224.
78. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61:705-714.
79. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57:M414-M418.
80. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63:1624-1628.
81. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statinassociated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-880.
82. Lavie CJ, Milani RV. Optimal lipids, statins, and dementia. J Am Coll Cardiol. 2005;45:963-964.
83. Orr JD. Statins in the spectrum of neurologic disease. Curr Atheroscler Rep. 2008;10:11-18.
84. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology. 2008;70:1418-1422.
85. Neuhaus O, Hartung HP. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother. 2007;7:547-556.
86. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol. 2010;67:1062-1067.
87. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
88. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69:878-885.
89. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology. 2005;64:1531-1538.
90. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80:13-17.
91. Sparks DL, Sabbagh M, Connor D, et al. Statin therap y in Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185: 78-86.
92. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:3-7.
93. Feldman HH, Doody RS, Kivipelto M, et al; LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956-964.
94. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19, Pt 2):1795-1802.